Free Trial

Uniphar (UPR) Stock Forecast & Price Target

Uniphar logo
GBX 174 +6.00 (+3.57%)
(As of 11/21/2024 ET)

Uniphar - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for Uniphar in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for UPR.

Consensus Price Target

GBX 310
According to the 1 analysts' twelve-month price targets for Uniphar, the average price target is GBX 310. The highest price target for UPR is GBX 310, while the lowest price target for UPR is GBX 310. The average price target represents a forecasted upside of 78.16% from the current price of GBX 174.
Get the Latest News and Ratings for UPR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Uniphar and its competitors.

Sign Up

UPR Analyst Ratings Over Time

TypeCurrent Forecast
11/23/23 to 11/22/24
1 Month Ago
10/24/23 to 10/23/24
3 Months Ago
8/25/23 to 8/24/24
1 Year Ago
11/23/22 to 11/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
N/A
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
N/A
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A
0 Sell rating(s)
Consensus Price TargetGBX 310GBX 310N/AN/A
Consensus Rating
Buy
Buy
N/A
Buy

UPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Uniphar Stock vs. The Competition

TypeUnipharMedical Companies
Consensus Rating Score
3.00
2.80
Consensus RatingBuyModerate Buy
News Sentiment Rating
Neutral News

See Recent UPR News
Neutral News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/4/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Reiterated RatingBuyGBX 310+36.56%
3/22/2023Shore Capital
1 of 5 stars
 Reiterated RatingBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:43 AM ET.


UPR Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Uniphar is GBX 310, with a high forecast of GBX 310 and a low forecast of GBX 310.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniphar in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" UPR shares.

According to analysts, Uniphar's stock has a predicted upside of 78.16% based on their 12-month stock forecasts.

Uniphar has been rated by research analysts at Deutsche Bank Aktiengesellschaft in the past 90 days.

Analysts like Uniphar more than other "medical" companies. The consensus rating for Uniphar is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how UPR compares to other companies.


This page (LON:UPR) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners